Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. [electronic resource]
Producer: 20061026Description: 1070-6 p. digitalISSN:- 1072-4710
- Antibodies, Monoclonal -- economics
- Antibodies, Monoclonal, Humanized
- Antiviral Agents -- economics
- Asthma -- economics
- Comorbidity
- Cost of Illness
- Cost-Benefit Analysis
- Decision Support Techniques
- Gestational Age
- Humans
- Infant, Newborn
- Infant, Premature
- Infant, Premature, Diseases -- economics
- Length of Stay
- Palivizumab
- Quality-Adjusted Life Years
- Respiratory Syncytial Virus Infections -- epidemiology
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.